Agile Therapeutics

Agile Therapeutics is the pharmaceutical company developing contraceptive healthcare products for women. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive patch.

In addition to Twirla, Agile is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of the Company's product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Company Growth (employees)
Type
Public
HQ
Princeton, US
Founded
1997
Size (employees)
19 (est)+12%
Agile Therapeutics was founded in 1997 and is headquartered in Princeton, US

Key People/Management at Agile Therapeutics

Al Altomari

Al Altomari

President & CEO & Board ofDirectors
Scott Coiante

Scott Coiante

Chief Financial Officer
C.Gregory Arnold

C.Gregory Arnold

Vice President of Manufacturing
Robert G.Conway

Robert G.Conway

Chief Development Officer, Vice President, Operations
Elizabeth Garner

Elizabeth Garner

Senior Vice President and Chief Medical Officer

Agile Therapeutics Office Locations

Agile Therapeutics has an office in Princeton
Princeton, US (HQ)
101 Poor Farm Rd

Agile Therapeutics Financials and Metrics

Agile Therapeutics Financials

USD

Net income (Q3, 2017)

(7.1 m)

EBIT (Q3, 2017)

(6.7 m)

Market capitalization (13-Dec-2017)

150.4 m

Cash (30-Sep-2017)

43.8 m
Agile Therapeutics's current market capitalization is $150.4 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

13.4 m25.6 m20.9 m

General and administrative expense

5.2 m7.5 m8.8 m

Operating expense total

18.5 m33.1 m29.7 m

EBIT

(18.5 m)(33.1 m)(29.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

R&D expense

2.4 m4.6 m5.4 m6.2 m7.2 m4.9 m5.6 m4.9 m4.7 m3.8 m

General and administrative expense

1.1 m1.4 m1.6 m1.8 m1.8 m2.1 m2.3 m2.2 m2.4 m3.2 m

Operating expense total

3.5 m6 m7 m8 m9 m7 m7.8 m7.1 m7.1 m7 m6.7 m

EBIT

(3.5 m)(6 m)(7 m)(8 m)(9 m)(7 m)(7.8 m)(7.1 m)(7.1 m)(7 m)(6.7 m)
USDFY, 2014FY, 2015FY, 2016

Cash

40.2 m34.4 m48.8 m

Accounts Receivable

539 m

Current Assets

41 m38.1 m51.5 m

PP&E

12 m12.3 m12.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

53.5 m45.7 m53.9 m46.4 m39.4 m65.5 m59.2 m51.7 m41.7 m33.9 m43.8 m

Inventories

1.6 m

Current Assets

54.2 m47 m54.4 m47.2 m40.7 m68.5 m61.3 m54.8 m44.3 m34.5 m45 m

PP&E

12.3 m12.3 m12.3 m12.3 m12.8 m
    USDFY, 2014FY, 2015FY, 2016

    Net Income

    (16.1 m)(30.3 m)(28.7 m)

    Depreciation and Amortization

    12.6 k18 k19 k

    Inventories

    (2.3 m)(1.2 m)922 k

    Accounts Payable

    2.6 m1.3 m362 k
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    (2.9 m)(9.2 m)(8.5 m)(17 m)(26.4 m)(7.3 m)(15.7 m)(23.5 m)(7.5 m)(15 m)(7.1 m)

    Depreciation and Amortization

    5 k7.7 k5 k10.1 k14.3 k4 k9 k14 k5 k11 k

    Inventories

    1.6 m

    Accounts Payable

    1.6 m2.2 m724.3 k1.2 m3 m(771 k)(768 k)(648 k)348 k(1.2 m)2.8 m
      Y, 2017

      Financial Leverage

      1.4 x
      Show all financial metrics

      Agile Therapeutics Operating Metrics

      FY, 2016

      Phase III Trials

      1

      Phase II Trials

      1

      Phase I Trials

      3

      Patents (US)

      13
      Show all operating metrics

      Agile Therapeutics Market Value History

      Agile Therapeutics's Web-traffic and Trends

      Agile Therapeutics Company Life and Culture

      You may also be interested in